{"id":77099,"date":"2026-05-07T14:49:18","date_gmt":"2026-05-07T14:49:18","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/77099\/"},"modified":"2026-05-07T14:49:18","modified_gmt":"2026-05-07T14:49:18","slug":"fda-glp-1-compounding-proposal-boosts-lly-nvo-and-hims-stock","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/77099\/","title":{"rendered":"FDA GLP-1 Compounding Proposal Boosts LLY, NVO, and HIMS Stock"},"content":{"rendered":"

Eli Lilly and Company NYSE: LLY<\/a> and Novo Nordisk A\/S NYSE: NVO<\/a> are two weight-loss and diabetes drug stocks that have been on completely different trajectories. Since the start of 2025, LLY is up nearly 30%, while NVO has plummeted more than 30%.<\/p>\n

Eli Lilly and Company Today\"EliLLY<\/a>\"LLY<\/a><\/p>\n

Eli Lilly and Company<\/p>\n

$978.50 -8.55\u00a0(-0.87%) As of 10:49 AM Eastern This is a fair market value price provided by Massive. Learn more.<\/a>52-Week Range$623.78<\/p>\n

\u25bc<\/p>\n

$1,133.95<\/p>\n

Dividend Yield0.71%<\/p>\n

P\/E Ratio34.76<\/p>\n

Price Target$1,217.59<\/p>\n

Get Eli Lilly and Company alerts:<\/p>\n

Sign Up<\/p>\n

This comes as Eli Lilly has taken massive market share from Novo. In its latest quarter, Eli Lilly posted revenue growth of 56% year over year (YOY)<\/a>. For the full-year 2026, the midpoint of Lilly\u2019s guidance implies growth of 28% YOY.<\/p>\n

Meanwhile, Novo expects its constant currency sales to fall by 5% to 13% YOY in 2026<\/a>, a massive step down from growth of 36% in 2023. Much of the difference in their revenue growth is due to Lilly\u2019s GLP-1 tirzepatide. Branded as Mounjaro and Zepbound, the drug induces around 47% more weight loss<\/a> than Novo\u2019s semaglutide.<\/p>\n

Despite their battle, the companies recently received news that both can cheer about. The Food and Drug Administration has proposed<\/a> to exclude tirzepatide and semaglutide from its 503B bulk list. Here\u2019s what that means for Lilly and Novo going forward.<\/p>\n

FDA Looks to Stop 503B Compounding for Good\u2014Lilly and Novo Score<\/p>\n

When an approved drug is in shortage, the FDA allows 503A compounding pharmacies and 503B outsourcing facilities to compound copies of the drug. After the FDA added tirzepatide and semaglutide to the shortage list in 2022, companies like Hims & Hers Health built businesses around compounding GLP-1s. Hims has utilized both 503A and 503B facilities<\/a> to source its drugs in the past.<\/p>\n

Hims & Hers Health Today\"HimsHIMS<\/a>\"HIMS<\/a><\/p>\n

Hims & Hers Health<\/p>\n

$26.14 -0.74\u00a0(-2.75%) As of 10:49 AM Eastern This is a fair market value price provided by Massive. Learn more.<\/a>52-Week Range$13.74<\/p>\n

\u25bc<\/p>\n

$70.43<\/p>\n

P\/E Ratio51.38<\/p>\n

Price Target$31.86<\/p>\n

Shortages for both drugs ended between 2024 and 2025, but Hims operated in a legal gray area to continue selling. According to Pharmacy Times<\/a>, the proposal’s passing would \u201cforeclose any future pathway\u201d for 503B facilities to compound the drugs, \u201ceven in the event of a new shortage designation.” In other words, there would be no going back.<\/p>\n

For Lilly and Novo, this would be a clear win. Compounders have siphoned off demand for their drugs that would otherwise go to them. The proposal would remove the ability of 503B facilities to do this in the future. For 503A, that future opportunity is still there, although it is technically prohibited to sell these drugs under that status, as the shortages are over. Still, Hims clearly demonstrates how regulators have not fully enforced this.<\/p>\n

Notably, Novo shares rose by 4.8% on the day of this April 30 announcement, showing that investors saw it as a meaningful piece of positive news. Lilly rose 9.8% that day, and though the announcement coincided with the firm\u2019s highly impressive earnings report<\/a>, it is likely that the news also contributed to Lilly\u2019s significant gain.<\/p>\n

Hims Gains as Investors Weigh Compounding Regulation<\/p>\n

For Hims and Hers, the benefit is more nuanced but still legitimate. The company recently signed a deal with Novo<\/a>, allowing it to formally sell semaglutide and oral semaglutide. With this proposal, the group of compounders that Hims competes with weakens.<\/p>\n

With its Novo agreement, Hims can sell branded (AKA non-compounded) versions of the company\u2019s GLP-1s. This means that the FDA proposal should not limit Hims’s ability to sell Novo\u2019s drugs. However, it would impact the ability of some compounders to do the same in the future, putting Hims in a stronger position.<\/p>\n

In a statement to Reuters<\/a>, a Hims & Hers spokesperson said the company does not expect the proposal to impact its business. Hims noted that \u201cthere are no GLP\u20111s compounded by 503B facilities accessible through our platform.\u201d Hims shares rose by approximately 3.2% on the day of the proposal.<\/p>\n

Hims can also continue to sell Lilly\u2019s drugs. However, the firm does not have the same type of agreement that it does with Novo. Accessing Lilly\u2019s drugs through Hims acts more like a referral arrangement, directing users to Lilly. Hims’ own announcement<\/a> says, \u201cAccess to Zepbound and Foundayo does not imply a partnership or affiliation with Eli Lilly and Company.”<\/p>\n

Due to this, it\u2019s very unlikely that Hims receives any direct financial benefit from offering Lilly\u2019s drugs. However, Hims may be able to gain or retain members who would have looked to other telehealth platforms to access Lilly\u2019s treatments.<\/p>\n

Lilly Continues to Dominate the GLP-1 Arena<\/p>\n

Overall, Eli Lilly and Novo should get added protection for their valuable GLP-1 drugs. The proposal is not final at this point. However, as it came from the decision-maker itself (the FDA), it is likely to be enacted.<\/p>\n

Hims is an under-the-radar winner from the proposal on the semaglutide side, given its formally established relationship with Novo.<\/p>\n

However, among these names, Eli Lilly is clearly in the strongest position. The company demonstrated that it doesn\u2019t need to make a deal with Hims like Novo did. Rather, it is taking all the spoils from its top-performing weight-loss and diabetes medications.<\/p>\n

Before you consider Eli Lilly and Company, you’ll want to hear this.<\/p>\n

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks<\/a> that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Eli Lilly and Company wasn’t on the list.<\/p>\n

While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.<\/p>\n

View The Five Stocks Here <\/a><\/p>\n

\"Don't<\/p>\n

The space race is growing fast, and you don\u2019t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.<\/p>\n

Get This Free Report<\/a><\/p>\n

Like this article? Share it with a colleague.<\/p>\n

<\/a><\/a><\/a><\/a><\/a><\/a><\/a><\/p>\n

Link copied to clipboard.<\/p>\n